| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
The first AI Software dedicated to the insurance industry. Reenchant the relationship with your customers by using our ready-to-use and trustworthy AI!
zerologic is a Broomfield, CO-based company in the Software and Internet sector.
We are building the future of software development.
For nearly two decades neon has simplified Workforce Management through thoughtful technology solving the HR needs of clients in over 75,000 locations.